Therapeutic intervention with either anti-CotH or anti-GRP78 antibodies protects neutropenic and diabetic ketoacidosis mice against mucormycosis, highlighting the significance of CotH/ GRP78 protein interactions in the pathophysiology of mucormycosis [69,70,85]. This evidence concerns the gene HSPA5 and diabetic ketoacidosis.